Cargando…

Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer

PURPOSE: The study of plasma cell-free DNA integrity (cfDI) has shown potential for providing useful information in neoplastic patients. The aim of this study is to estimate the accuracy of an electrophoresis-based method for cfDI evaluation in the assessment of pathologic complete response (pCR) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirmena, Gabriella, Ferrando, Lorenzo, Ravera, Francesco, Garuti, Anna, Dameri, Martina, Gallo, Maurizio, Barbero, Valentina, Ferrando, Fabio, Del Mastro, Lucia, Garlaschi, Alessandro, Friedman, Daniele, Fregatti, Piero, Ballestrero, Alberto, Zoppoli, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974578/
https://www.ncbi.nlm.nih.gov/pubmed/35201850
http://dx.doi.org/10.1200/PO.21.00198
_version_ 1784680243484688384
author Cirmena, Gabriella
Ferrando, Lorenzo
Ravera, Francesco
Garuti, Anna
Dameri, Martina
Gallo, Maurizio
Barbero, Valentina
Ferrando, Fabio
Del Mastro, Lucia
Garlaschi, Alessandro
Friedman, Daniele
Fregatti, Piero
Ballestrero, Alberto
Zoppoli, Gabriele
author_facet Cirmena, Gabriella
Ferrando, Lorenzo
Ravera, Francesco
Garuti, Anna
Dameri, Martina
Gallo, Maurizio
Barbero, Valentina
Ferrando, Fabio
Del Mastro, Lucia
Garlaschi, Alessandro
Friedman, Daniele
Fregatti, Piero
Ballestrero, Alberto
Zoppoli, Gabriele
author_sort Cirmena, Gabriella
collection PubMed
description PURPOSE: The study of plasma cell-free DNA integrity (cfDI) has shown potential for providing useful information in neoplastic patients. The aim of this study is to estimate the accuracy of an electrophoresis-based method for cfDI evaluation in the assessment of pathologic complete response (pCR) in patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT). PATIENTS AND METHODS: Fifty-one patients with BC undergoing anthracycline-/taxane-based NACT were recruited. Plasma samples were collected from each patient at diagnosis (t0), after anthracycline administration (t1), and after NACT completion (t2). The concentration of differently sized cell-free DNA fragments was assessed by automated electrophoresis. cfDI, expressed as cfDI index, was calculated as the ratio of 321-1,000 bp sized fragment concentration to 150-220 bp sized fragment concentration assessed at t2. cfDI index was then used to build an exploratory classifier for BC response to NACT, directly comparing its sensitivity and specificity with magnetic resonance imaging (MRI), through bootstrapped logistic regression. RESULTS: cfDI index was assessed on 38 plasma samples collected from as many patients at t2, maintaining a 30/70 ratio between pCR and non-pCR patients. cfDI index showed an area under the receiver operating characteristic curve in predicting the achievement of pCR of 81.6, with a cutoff above 2.71 showing sensitivity = 81.8 and specificity = 81.5. The combination of cfDI index and MRI showed, in case of concordance, an area under the receiver operating characteristic curve of 92.6 with a predictive value of complete response of 87.5 and a predictive value of absence of complete response of 94.7. CONCLUSION: cfDI index measured after NACT completion shows great potential in the assessment of pCR in patients with BC. The evaluation of its use in combination with MRI is strongly warranted in prospective studies.
format Online
Article
Text
id pubmed-8974578
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-89745782022-04-04 Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer Cirmena, Gabriella Ferrando, Lorenzo Ravera, Francesco Garuti, Anna Dameri, Martina Gallo, Maurizio Barbero, Valentina Ferrando, Fabio Del Mastro, Lucia Garlaschi, Alessandro Friedman, Daniele Fregatti, Piero Ballestrero, Alberto Zoppoli, Gabriele JCO Precis Oncol ORIGINAL REPORTS PURPOSE: The study of plasma cell-free DNA integrity (cfDI) has shown potential for providing useful information in neoplastic patients. The aim of this study is to estimate the accuracy of an electrophoresis-based method for cfDI evaluation in the assessment of pathologic complete response (pCR) in patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT). PATIENTS AND METHODS: Fifty-one patients with BC undergoing anthracycline-/taxane-based NACT were recruited. Plasma samples were collected from each patient at diagnosis (t0), after anthracycline administration (t1), and after NACT completion (t2). The concentration of differently sized cell-free DNA fragments was assessed by automated electrophoresis. cfDI, expressed as cfDI index, was calculated as the ratio of 321-1,000 bp sized fragment concentration to 150-220 bp sized fragment concentration assessed at t2. cfDI index was then used to build an exploratory classifier for BC response to NACT, directly comparing its sensitivity and specificity with magnetic resonance imaging (MRI), through bootstrapped logistic regression. RESULTS: cfDI index was assessed on 38 plasma samples collected from as many patients at t2, maintaining a 30/70 ratio between pCR and non-pCR patients. cfDI index showed an area under the receiver operating characteristic curve in predicting the achievement of pCR of 81.6, with a cutoff above 2.71 showing sensitivity = 81.8 and specificity = 81.5. The combination of cfDI index and MRI showed, in case of concordance, an area under the receiver operating characteristic curve of 92.6 with a predictive value of complete response of 87.5 and a predictive value of absence of complete response of 94.7. CONCLUSION: cfDI index measured after NACT completion shows great potential in the assessment of pCR in patients with BC. The evaluation of its use in combination with MRI is strongly warranted in prospective studies. Wolters Kluwer Health 2022-02-24 /pmc/articles/PMC8974578/ /pubmed/35201850 http://dx.doi.org/10.1200/PO.21.00198 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Cirmena, Gabriella
Ferrando, Lorenzo
Ravera, Francesco
Garuti, Anna
Dameri, Martina
Gallo, Maurizio
Barbero, Valentina
Ferrando, Fabio
Del Mastro, Lucia
Garlaschi, Alessandro
Friedman, Daniele
Fregatti, Piero
Ballestrero, Alberto
Zoppoli, Gabriele
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
title Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
title_full Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
title_fullStr Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
title_full_unstemmed Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
title_short Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
title_sort plasma cell-free dna integrity assessed by automated electrophoresis predicts the achievement of pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974578/
https://www.ncbi.nlm.nih.gov/pubmed/35201850
http://dx.doi.org/10.1200/PO.21.00198
work_keys_str_mv AT cirmenagabriella plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT ferrandolorenzo plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT raverafrancesco plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT garutianna plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT damerimartina plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT gallomaurizio plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT barberovalentina plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT ferrandofabio plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT delmastrolucia plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT garlaschialessandro plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT friedmandaniele plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT fregattipiero plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT ballestreroalberto plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer
AT zoppoligabriele plasmacellfreednaintegrityassessedbyautomatedelectrophoresispredictstheachievementofpathologiccompleteresponsetoneoadjuvantchemotherapyinpatientswithbreastcancer